ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis

BACKGROUND: In bone metastatic castration-resistant prostate cancer (bmCRPC) treated with Enzalutamide commonly used prostate-specific antigen (PSA) can be misleading since initial PSA-flares may occur. In other therapies, bouncing of alkaline phosphatase (ALP-bouncing) was shown to be a promising s...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlack, Katrin, Krabbe, Laura-Maria, Rahbar, Kambiz, Isenberg, Karoline, Semjonow, Axel, Schrader, Andres Jan, Boegemann, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article on Management of Advanced Genitourinary Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575579/
https://www.ncbi.nlm.nih.gov/pubmed/34804841
http://dx.doi.org/10.21037/tau-20-1117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575579/
https://www.ncbi.nlm.nih.gov/pubmed/34804841
http://dx.doi.org/10.21037/tau-20-1117

Ejemplares similares